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Abstract 
 
Background: The pathology of chronic wounds is often characterised by elevated 
levels of pro-inflammatory cytokines (e.g. tumour necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β)), proteases (e.g. matrix metalloproteinases (MMPs)) and 
neutrophil elastase. MMPs specifically have been implicated by a number of studies 
as the major protease family responsible for the degradation of key factors critical to 
the ulcer’s ability to heal. 
Objectives: To assess individual MMPs in CWF to develop improved treatments for 
chronic ulcers. 
Methods: Collagen Type I and IV zymography, immunoprecipitation followed by a 
substrate activity assay, and an indirect enzyme-linked immunosorbant assay (ELISA) 
were all used to analyse MMP levels in CWF. 
Results: Our studies demonstrate that there is excessive protease activity in chronic 
wound fluid (CWF) compared with both human serum (HS) and acute wound fluid 
(AWF), which can be specifically attributed to MMPs as determined through a MMP-
inhibitor study. Multiple MMPs were then immunoprecipitated from the CWF 
samples and MMP-9 was identified as the predominant protease in CWF, with 
significantly elevated activity levels in CWF compared with AWF. In addition, the 
clinical status of the ulcer is directly associated with the amounts of MMP-9 present 
in the wound fluid. Therefore, this study suggests that higher levels of MMP-9 in 
chronic wound fluid correlate with a clinically worse wound. 
Conclusions: In view of these results, it is hypothesised that a specific inhibitor of 
MMP-9 could potentially be more therapeutically effective than general MMP 
inhibitors in modulating chronic ulcers towards a healing state.  
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1. Introduction  
 
Wound healing is a highly complex process that can lead to chronic ulcers if any stage 
in this intricate series of events is interrupted1. While there is no single reported cause 
of these ulcers, many factors are considered important when distinguishing chronic 
wounds from their acute counterparts. Predominantly, these wounds are characterised 
by excessive granulation tissue and increased fibrosis2, along with significant 
increases in pro-inflammatory cytokines, proteases and neutrophil elastase3-6. 
Furthermore, excessive inflammation caused by an hyper-stimulated neutrophil 
response has also been suggested as a potential cause for a wound’s chronicity7. This 
can be further exacerbated by susceptibility of open wounds to infection8. It is this 
protease activity, primarily caused by a specific group of proteases called matrix 
metalloproteinases (MMPs), that is believed to be responsible for the increased 
extracellular matrix destruction observed in chronic wounds3. However, there is 
considerable conflicting information in the literature concerning both the under- and 
over-expression of specific MMPs in chronic wounds. 
 
Gelatinases, also referred to as MMP-2 (gelatinase-A) and MMP-9 (gelatinase-B), are 
thought to have an extremely important function in normal wound healing during both 
the remodelling and re-epithelialisation phases, and it has been proposed that wound 
healing would be impaired if they were inhibited9. Conversely, other reports have 
suggested that both MMP-2 and MMP-9, when present at the significantly higher 
activity levels reported for chronic wounds, need to be inhibited to allow normal 
healing to occur6,10. The main reason why gelatinases are so important is that they are 
able to break down collagen more effectively than other MMPs11, as well as cleave 
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the major constituent of the basement membrane – collagen type IV4. Indeed, MMP-9 
was shown to be able to cleave collagen types I-V into small peptides at the 
physiological temperature of 37 ºC12. In addition, MMP-2 has been shown to play an 
important role in the reorganisation of collagen lattices in vitro13, as well as being 
only one of two MMPs found to play an active role in non-injured skin11. 
 
MMP-9 is produced by a number of different cell types, namely inflammatory cells, 
neutrophils, macrophages, monocytes and keratinocyte10,14. As chronic ulcers are 
classified as non-healing, the MMP-9 present is CWF is thought to be either 
neutrophil- or macrophage-derived, since these are the main cells present in an open 
non-healing ulcer14. In terms of MMP-9 expression in chronic ulcers, one study 
demonstrated that MMP-9 is temporally expressed during the healing of chronic 
wounds10. This also correlates with another report that showed MMP-9 activity levels 
in CWF were 25-fold elevated over a normal control15. In contrast, Cullen et al. 
(2002) reported a lack of MMP-2 in CWF, which as MMP-2 is fibroblast-derived, 
suggests that there must a lack of fibroblasts in these chronic wounds and hence 
perhaps underlying the lack of wound closure14. 
 
In order to provide some clarity as to the role of MMPs in chronic ulcers, we elected 
to more fully examine these proteases in CWF. This choice of clinical sample was 
adopted as the longer term goal of this research was to develop a wound dressing to 
modulate this fluid. In addition, most investigators focus on total protease activity in 
CWF rather than individual proteases; therefore we were interested in examining 
individual MMP species using multiple detection techniques. It was hoped that this 
approach would help clarify the variable and conflicting data previously published on 
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MMPs in chronic wounds. Furthermore, our studies focussed on MMP-9 as it was 
identified through our studies to be the major MMP in CWF. In addition, it has the 
ability to cleave a number of substrates, as well as being produced mainly in 
inflammatory cells – with these cells hypothesised as being major contributors to an 
ulcer’s chronicity. Finally, the clinical status of the ulcer was considered in relation to 
MMP-9 protease activity to establish if there was an association between the two.  
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Materials and Methods 
 
Wound fluid sample collection and preparation 
 
Chronic wound fluid (CWF) samples were obtained from consenting patients of the 
St. Luke’s Nursing Services (Brisbane, QLD, Australia) suffering from chronic 
venous ulcers undergoing compression therapy (Table 1). Ethical approval to collect 
these samples was obtained from both the Queensland University of Technology 
(QUT) and St. Luke’s Nursing Services. A standard wound fluid collection technique 
has been established and was carried out at the clinical site. In addition, patients 
exhibiting infections in their ulcers were excluded from the study. Briefly, ulcers were 
washed with sterile water prior to collecting wound fluid, followed by the application 
of an occlusive dressing over the wound16. Exudate accumulated under the dressing 
after 30 min to 1 h was recovered by washing with 1 mL of saline. Three separate 
acute wound fluid (AWF) samples were collected from naturally occurring sub-
epidermal blisters on the feet of volunteers. The fluid was removed with 26G x 0.5” 
needle and syringes (Terumo Medical, Somerset, NJ, USA) and collected in 1.5 mL 
Protein LoBind tubes (Eppendorf, Hamburg, Germany). The wound fluid samples 
were centrifuged at 14,000 g for 10 min, then the supernatant filtered using 0.45 µm 
cellulose acetate filters (Agilent Technologies, Wilmington, DE, USA). This wound 
fluid collection technique was chosen as being the most suitable approach, primarily 
because it does not rely on the absorption of wound fluid on to a porous, hydrophilic 
wound dressing. In particular, the use of absorption techniques has been reported to 
result in lower sample volume and protein amount17. In addition, other techniques that 
rely on this absorption approach do not take into account that proteins may 
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differentially adhere to these dressings, which will then influence the CWF sample in 
later analyses18. A pooled human serum (HS) sample was purchased commercially 
from Sigma-Aldrich (St Louis, MO, USA). Protein content for all samples was 
quantitated and standardised using the BCA Protein assay kit (Pierce Biotechnology, 
Rockford, IL, USA). The samples were then sub-aliquoted and stored at -80 ºC until 
further analysis. 
 
Identification of protease activity using collagen zymography 
 
Collagen zymography was performed as previously described19 using Collagen Type I 
and Collagen Type IV (Sigma-Aldrich) at a final concentration of 0.5 mg/mL in 10% 
total acrylamide gels under non-reducing conditions. Briefly, electrophoresis was 
performed at 4 ºC under Laemmli conditions20. The gels were then washed in 2.5% 
Triton X-100 for 30 minutes, then a further 60 minutes, prior to incubation in 50 mM 
Tris-HCl, 10 mM CaCl2, 50 mM NaCl at pH 7.6 for 24 hours at 37 ºC. The gels were 
then stained using 0.25% Coomassie brilliant blue R-250 (Bio-rad Laboratories, 
Hercules, CA, USA) (40% methanol, 10% acetic acid) and destained appropriately 
(40% methanol, 10% acetic acid). Protease activity was visualised as clear (unstained) 
bands.  
 
Analysis and quantitation of collagen zymography 
 
Gels were scanned using GeneSnap version 6.07 (SynGene, Cambridge, UK) and 
analysed using GeneTools version 3.07 to quantitate the clear bands (SynGene). All 
quantitations were performed using the analysis of 3 separate gels per treatment and 
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values were expressed as a relative % of the MMP standard, similar to previously 
published reports13,21. The data was also analysed in terms of grouping the samples 
based on the “PUSH” score of the wounds from which the CWF was collected. 
Clinicians use the PUSH (Pressure Ulcer Scale of Healing) score to grade the wounds 
(1 = best, 17 = worst) with this value taking into account a number of factors to score 
the ulcer22. While this measurement technique was originally designed by the 
National Pressure Ulcer Advisory Panel to grade pressure ulcers, it has also been 
validated as an effective tool to monitor healing trends in venous ulcers22. Thus, 
Ratliff et al. (2005) noted that this system was a simple, valid and reliable tool for 
monitoring venous ulcer clinical status22. In view of this, the data in our study was 
organised in terms of PUSH score, with five samples (CWF-1, -2, -3, -4, -5) 
exhibiting a high PUSH score (≥12) and four samples (CWF-6, -7, -8, -9) showing a 
lower PUSH score (≤11). While we ideally would have preferred to assess a greater 
number of samples, CWF sample numbers were restricted due to patient availability, 
as well as the amount of protein required from individual samples to complete the full 
spectrum of experiments reported here. 
 
Confirmation of MMP-specific collagen degradation using GM6001 inhibitor  
 
To confirm that the collagen degrading activity visualised through zymography was 
due to MMPs, a specific MMP inhibitor, GM6001 (Ilomastat or N-[(2R)-2-(hydrox-
amidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide) (Chemicon, 
Temecula, CA, USA) was used. Increasing concentrations of GM6001 (1, 3, 10, 30, 
100, 300 and 1000 µM) were incubated with CWF-1 samples at 37 ºC for 24 hours. 
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These samples were then run on Collagen Type I zymograms and analysed as 
described above. 
 
Specific identification of individual MMPs through immunoprecipitation 
 
Further confirmation of MMP activity was established through the 
immunoprecipitation of specific MMPs followed by collagen zymography. UltraLink 
Immobilized Protein A/G resin (Pierce Biotechnology) was incubated with individual 
MMP antibodies in a Tris-buffered saline solution with 0.1% Tween-20 (TBST) and 
rotated for 5 hours at 4 ºC in 0.5 mL Protein LoBind tubes (Eppendorf). The 
antibodies were: a mouse mAb for human MMP-9 (Ab-7) (Calbiochem, San Diego, 
CA, USA); a rabbit pAb for human MMP-8 (Chemicon); and a rabbit pAb for human 
MMP-13 N-terminal (Chemicon).  Following incubation, the solution was centrifuged 
at 2,000 rpm for 2 minutes, the supernatant removed, and the resin then washed twice 
with TBST. This “charged” resin was then incubated with the human serum, AWF 
and CWF samples for 18 hours at 4 ºC, constantly rotating. As before, following 
incubation the solution was centrifuged at 2,000 rpm for 2 minutes, the supernatant 
removed, and the resin was washed twice with TBST. The resin was then mixed with 
a 2X SDS sample buffer and left at room temperature for 1 hour. To examine the 
bound proteins, these resin samples were run on Collagen Type I zymograms and 
analysed as described above. 
 
Quantitative confirmation of MMP-9 levels through a direct enzyme- linked 
immunosorbant assay (ELISA) 
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Quantitative MMP-9 levels in HS, AWF and CWF samples were obtained using a 
direct ELISA. Briefly, 96-well plates (Nunc) were coated with 40 ng of the 
sample/well and left overnight at 4 ºC. Next, the wells were washed three times with 
TBST and blocked with 5% skim milk powder (SMP) in TBST for 1 hour at room 
temperature. Wells were again washed with TBST and then probed with a rabbit 
polyclonal antibody (1:1000) raised against the MMP-9 whole molecule (Abcam, 
Cambridge, UK) for 1 hour at room temperature. Following washing, the wells were 
probed with polyclonal goat anti-rabbit immunoglobulins/HRP (1:1000) (Dako 
Denmark A/S, Glostrup, Denmark) for 1 hour at room temperature. Then, the wells 
were again washed and rinsed a final time with TBS before adding the substrate 
solution, 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) (Sigma-
Aldrich) for 30 minutes at room temperature. The optical density of the plate was then 
read at 405 nm on a standard plate reader (Bio-rad Laboratories). The amount of 
MMP-9 in the samples was calculated from a standard curve and then converted to 
MMP-9 (ng)/total sample protein (μg). Data was organised in terms of the sample’s 
PUSH score. 
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Results 
 
Elevated proteolytic activity in chronic wound fluid 
 
In order to analyse the proteolytic activity in wound fluid samples, CWFs from nine 
separate patients (Table 1) were analysed using Collagen Type I and Collagen Type 
IV zymography to identify protease activity. In addition, human serum (HS) and acute 
wound fluid (AWF, n=3) samples were analysed. Collagens were used for the 
zymography studies as they are the major extracellular matrix constituents of the skin, 
contributing to approximately 70% of its dry weight. Furthermore, Collagen Type I 
accounts for approximately 80% of the skin collagens, while Collagen Type IV forms 
the basement membrane23, an important structure that is commonly disrupted in large 
non-healing ulcers. It is noted that there are other extracellular matrix proteins 
important in epithelial wound healing, e.g. Collagen Type III24 and fibronectin25, but 
for the purposes of this study only Collagens Type I and IV were investigated. 
Collagen degrading activity was identified as clear bands on a dark background in the 
zymograms, with some smearing evident in the standards, as seen previously by 
others26. Ten times more total protein of both the HS and AWF samples had to be 
loaded on the gels in order to adequately visualise the collagenase-like activity on 
both substrates. As shown in Figures 1-2, the degradation profiles vary between the 
patient samples in terms of both intensity and molecular weight of the visualised 
bands. However, the bands appear to be consistent between the two different 
substrates. 
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More specifically, Collagen Type I zymography revealed a high level of protease 
activity in the CWF samples (lanes 6-14), especially considering the lower amount of 
the sample loaded (Figure 1). In addition to the main band at approximately 102 kDa, 
there are also smaller and potentially more active forms visible at 75 kDa, 66 kDa and 
54 kDa across the samples. Compared to CWF, less protease activity was evident in 
both the HS (lane 2) and AWF samples (lanes 3-5), especially considering the 
increased amount of protein loaded in these lanes for these samples. The main band in 
the AWF samples correlates with a mass of 66 kDa, similar to the main band seen in 
the HS. CWF-6 (lane 11) appears to have less proteolytic activity than the other CWF 
samples, however, the activity present was greater than that found with the HS and 
AWF samples.  
 
Similar to the results found with the Collagen Type I zymography, Collagen Type IV 
zymography also revealed increased levels of protease activity in CWF (lanes 6-14) as 
compared with HS (lane 2) and AWF samples (lanes 3-5) (Figure 2). The main band 
in CWF is visualised at 102 kDa, suggesting that this is the same protease as 
identified with Collagen Type I zymography. The main differences observed with 
Collagen Type IV zymography, as compared to Collagen Type I zymography, are that 
firstly, there seem to be less bands of lower molecular weight activity with this 
substrate, and also, the amount of proteolytic activity is reduced when taking into 
account the fact that twice the amount of sample was loaded. 
  
MMPs are responsible for collagen degradation as shown through a MMP 
specific inhibitor study 
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The MMP-specific inhibitor, GM6001, was used to confirm that the collagen 
degradation revealed by zymography was indeed due to MMPs and not another group 
of proteases present in the wound fluid samples. Through incubation with increasing 
concentrations of GM6001 at 37 ºC over 24 hours, the proteolytic activity in CWF-1 
gradually decreased as revealed by Collagen Type I zymography. Indeed, no visible 
degradation of collagen was apparent at 1 mM GM6001 (lane 9) (Figure 3a). 
Densitometry was used to quantify the reduction in proteolytic activity revealed by 
zymography, and the levels are represented graphically in Figure 3b. Both the total 
amount of protease activity, plus the protease activity in individual molecular weight 
species, was followed across the increasing concentrations of 1, 10, 100 and 1,000 
µM concentrations of GM6001 and the data is expressed as relative % of the untreated 
CWF-1 ± SEM. In all cases, the collagen degrading activity decreases when 
increasing concentrations of the MMP-specific inhibitor are present, confirming that 
the majority of the proteases responsible for collagenase-like activity in these CWF 
samples are from the MMP family. 
 
Initial immunoprecipitation of MMPs from CWF samples 
 
Following confirmation that the majority of collagen-degrading activity seen in CWF 
samples was due to MMP-specific activity, individual MMPs were 
immunoprecipitated from the CWF samples. Thus, individual MMP antibodies were 
linked to a protein A/G resin and then incubated with the CWF samples. Antibodies 
for MMP-1, -8 and -13 were used to identify particular species in terms of relative 
abundance when compared to the complete samples (Figure 1). In view of this, six 
CWF samples were analysed separately using specific immunoprecipitation of MMP-
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8, followed by analysis through Collagen Type I zymography as described previously. 
There appeared to be minimal MMP-8 activity across all 6 CWF samples containing 
the MMP-8 enriched fractions (Figure 4a). MMP-13 was also analysed across the 
same 6 CWF samples and revealed similar results (Figure 4b). Similarly, MMP-1 was 
examined in select samples (data not shown) and again, minimal activity was present. 
Positive controls of individual purified MMP proteins were also run in parallel to 
ensure that these reduced results were not simply due to laboratory analysis, and 
therefore were indeed indicative of the MMP levels in the CWF samples. Thus, the 
levels of MMP-1, -8 and -13 present in the samples were insufficient to cause the 
majority of Collagen Type I degrading activity as revealed in the complete CWF 
samples through zymography (Figure 1).  
 
MMP-9 is the predominant protease responsible for matrix degradation in 
chronic wound fluid 
 
The CWF samples were then investigated for MMP-9 activity levels since MMP-9 
can cleave collagen types I-V 12, and because previous reports suggested excessive 
levels of MMP-9 were present in CWF 15. Through incubation with a MMP-9 
monoclonal antibody linked to a A/G protein resin, MMP-9 was analysed in terms of 
relative abundance within HS, AWF and CWF samples. Both the bound and unbound 
fractions from the MMP-9 immunoprecipitation step were analysed through Collagen 
Type I zymography and then quantitated through densitometric analysis. The 
degradation profiles obtained via zymography varied in terms of both abundance and 
molecular weight of the proteolytic activity. Samples were also analysed in terms of 
grouping the samples based on the “PUSH” score of the wounds from which the CWF 
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was collected. Clinicians use the PUSH (Pressure Ulcer Scale of Healing) score to 
grade the wounds (1 = best, 17 = worst) with this value taking into account a number 
of factors, i.e. ulcer size, exudate amount and tissue type, to score the ulcer22. This 
therefore allows a more complete clinical picture to be shown, instead of simply 
relying on single parameters, e.g. ulcer duration. However, previously reported 
indicators, e.g. ulcer size27, also score quite highly on the PUSH scale, which is shown 
through further analysis of the patient data in Table 1 (Patient 3, ulcer size = 84 cm2, 
PUSH = 15).  
 
The MMP-9-enriched fractions of CWF, that is the fraction that bound to the MMP-9 
antibody-linked resin, showed high levels of Collagen Type I degrading activity 
(Figure 5a). However, there was minimal activity in the MMP-9-enriched fractions of 
human serum and AWF samples, except for AWF-2. The molecular weight profile in 
these bound fractions appeared quite similar to the Collagen Type I zymograms of the 
complete samples (Figure 1), possibly indicating that MMP-9 was indeed the major 
constituent of the collagen degrading activity in the wound fluids. Quantitatively, 
there were significant differences between HS and AWF-2 (p<0.05), and with all 
CWF samples (p<0.01), except for CWF-6 (Figure 5b). In terms of grouped samples, 
the CWF samples showed statistically significant increased collagenase-like activity 
(p<0.01) when compared to both HS and AWF samples (Figure 5c). Further detailed 
analysis of the samples in terms of the PUSH scores revealed that both the lower 
PUSH score (PUSH ≤11) grouped samples and the higher PUSH score (PUSH ≥12) 
grouped samples both had significantly increased MMP-9 activity compared to both 
HS and AWF samples (p<0.01) (Figure 5d).  
 
 16
MMP-9-depleted fractions, that is the fraction that did not bind to the MMP-9 
antibody-linked resin, showed lower levels of Collagen Type I degrading activity 
(Figure 6a) than both the unfractionated samples (Figure 1) and MMP-9-enriched 
fractions (Figure 5a). Furthermore, there were increased levels of collagenase-like 
activity in the depleted fractions of CWF samples 1-5 and 7-9, compared with HS, 
AWF samples and CWF-6. Quantitatively, the levels of MMP-9 activity were 
significantly increased in CWF samples 1-3 and 8-9 (p<0.01) and CWF-7 (p<0.05), 
with similar trends evident in CWF samples 4 and 5, although they were not 
statistically significant (Figure 6b). When the samples were grouped into their relative 
types, that is CWF versus AWF versus HS, the CWF samples displayed highly 
significant Collagen Type I degrading activity when compared with HS and AWF 
samples (p<0.01) (Figure 6c). In addition, analysis of the samples in terms of PUSH 
scores revealed that the higher PUSH score (PUSH ≥12) group had significantly 
increased MMP-9 activity compared to HS and AWF samples (p<0.01), as well as the 
lower PUSH score (PUSH ≤11) group (p<0.05). In addition, the lower PUSH score 
(PUSH ≤11) group was not significantly different from either HS or AWF samples. 
The main differences in the zymography profiles of the bound and unbound fractions 
were at an approximate molecular weight of 65 and 55 kDa respectively. Therefore, 
from these results it appears that increased levels of MMP-9 activity are significantly 
different in CWF, as compared with both HS and its acute counterpart, in terms of 
both activity and molecular weight species. In addition, the fractions that had been 
depleted of MMP-9 appear to display a trend towards a higher level of Collagen Type 
I degrading activity correlating with a higher PUSH score, i.e. a clinically worse ulcer. 
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MMP-9 levels present in chronic wound fluid correlate with the clinical severity 
of the ulcer 
 
To confirm the findings found by immunoprecipitation, a direct ELISA was used with 
a different MMP-9 antibody to ensure accuracy in antibody specificity. MMP-9 levels 
for all samples ranged from approximately 70 ng/µg total protein to 370 ng/µg total 
protein. In all AWF samples, there were no statistically significant differences in 
MMP-9 levels compared to HS. Concerning the CWF samples, CWF-8 displayed 
significantly increased levels of MMP-9 compared with HS (p<0.05), with CWF 
samples 1-3, 5 and 9 also showing statistically increased MMP-9 levels (p<0.01) 
(Figure 7a). When grouped samples were analysed, CWF showed a statistically 
significant increase in MMP-9 levels compared with both AWF and HS (p<0.01) 
(Figure 7b). In addition, when the samples were grouped according to their clinical 
PUSH score, the lower PUSH score (PUSH ≤11) group was not significantly different 
from HS, but did have statistically significant differences from both AWF and the 
higher PUSH score (PUSH ≥12) group (p<0.01) (Figure 7c). Furthermore, the higher 
PUSH score (PUSH ≥12) group showed a significant increase in MMP-9 levels 
compared with both HS and AWF (p<0.01) (Figure 7c). From these results it appears 
that there is a trend towards increased levels of MMP-9 correlating with an increased 
PUSH score, and hence a clinically worse ulcer. 
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Discussion 
 
A major factor responsible for the chronic nature of ulcers is believed to be the tissue-
destructive events mediated by certain endopeptidases28,29. These neutral 
endopeptidases are able to degrade the extracellular matrix at the ulcer’s physiological 
pH and can be classified into two groups: serine proteases and matrix 
metalloproteinases29. A previous study by Weckroth et al. (1996) showed that serine 
proteases of polymorphonuclear neutrophil origin, e.g. cathepsin G and elastase, were 
both low in activity in CWF30. For this reason, the studies reported herein focussed on 
MMPs.  
 
In terms of MMPs, there have been a number of studies measuring MMP activity in 
CWF, but many of these studies have only used general techniques to identify a broad 
range of MMPs e.g. the Azocoll assay1,4, gelatin zymography1,10,15,31 and antibody 
detection32. As most members of the MMP family are structured into three essential, 
characteristic and highly conserved domains33, it is often quite difficult to differentiate 
MMP species based on molecular weight alone. In addition, antibody assays that are 
based on specific MMPs often find it difficult to differentiate between closely related 
species, as there is a very close evolutionary relationship within the family, as is 
reflected by their highly conserved domains34. Indeed, this high degree of structural 
similarity is likely to be the main reason underlying the controversy surrounding 
levels of specific MMPs in chronic wounds. In view of this, the studies reported 
herein used multiple techniques to identify specific MMPs species. Together, the 
combination of an antibody-based identification assay with an activity assay has 
allowed more conclusive and robust results. Indeed, the findings reported herein 
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indicate that there are minimal levels of MMP-1, -8 and -13 activity in CWF, with 
MMP-9 being the most likely candidate responsible for Collagen Type I degradation 
in CWF. This was further confirmed by using a different MMP-9 antibody for the 
ELISA as compared with that employed for the immunoprecipitation studies.  
 
All nine CWF samples examined exhibit higher levels of MMP activity than the AWF 
and HS samples. While CWF-6 appears to have less MMP activity than the other 
CWF samples, it still contains more MMP activity than the HS and AWF samples. 
These differences within the sample groups, however, highlight the difficulties of 
dealing with CWF as a diagnostic sample; due to the heterogeneity of these samples, 
and the wounds from which they are obtained, it is often quite difficult to achieve 
statistically conclusive results. While there have been many studies using CWF from 
venous ulcers as a clinical indicator of the ulcer’s status, there is still a large amount 
of ambiguity in this area concerning sample collection, sample standardisation, and 
long-term storage35. Furthermore, variations in patient wound care, clinical measures 
and sample collection all contribute to the complications shown in this area of 
research36.  
 
While these sample limitations have to be considered, in the study we report here, it is 
clear that Collagen Type I and IV degradation by CWF samples is higher than that 
observed with HS and AWF samples. In addition, our data demonstrate that the 
collagen degradation can be specifically attributed to MMPs as shown through the 
targeted inhibitor study using GM6001, a specific MMP inhibitor37. Thus, GM6001 
was shown to inhibit the CWF-induced collagen degradation in a dose-dependent 
manner. Together, these data confirm the hypothesis that elevated MMP levels in 
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CWF are indicative of a clinically worse chronic ulcer and furthermore, suggest that 
inhibition of these proteases holds promise as a therapeutic treatment for these 
debilitating chronic wounds.  
 
More specifically, these experiments suggest that MMP-9 appears to be the major 
protease responsible for matrix degradation in CWF. This is similar to previous 
reports by Ladwig et al. (2002), which suggested that there was a statistically 
significant correlation between poor healing and elevated levels of MMP-9 in 
patients, regardless of the treatment regime6. Moreover, Wysocki et al. (1999) state 
that as healing proceeds, the levels of MMP-9 decrease in CWF and reach those found 
in acute wounds10. However, both of these studies relied on semi-quantitative data 
from quantitation of either gelatin zymography10 or both zymography and western 
blotting6. Therefore, while their results are important, they do not provide definitive 
evidence of statistically significant differences between ulcers with different clinical 
scores, which underpins the novelty of what we report here. Further evidence suggests 
that the MMP-9 present in CWF is derived from macrophages infiltrating the wound 
bed38, which considering the excessive levels of MMP-9 in CWF compared with 
AWF, could further confirm the hypothesis that chronic wounds are partly caused by 
disproportionate inflammation and the inability to proceed into the normal 
remodelling stage of wound healing3. Therefore, the clinically worse ulcers are those 
that show prolonged inflammation, presenting as increased levels of macrophage-
derived MMP-9 in the resultant CWF. 
 
In this study, CWF samples were organised according to their PUSH score, which is a 
clinical score used to grade the ulcer taking into account a number of factors22. While 
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this system was originally created for use with pressure ulcers, it has since been 
validated as a straightforward, reliable tool for observing venous ulcer clinical 
status22. In the results reported herein, the lower and higher PUSH score groups  were 
indistinguishable through immunoprecipitation, as both groups showed a significant 
increase in MMP-9 activity compared with HS and AWF samples (p<0.01). Similar 
results have been obtained in previous studies, with MMP-9 in CWF showing a 
minimum of a 2-fold increase when compared with AWF and HS6,10. When 
considering the MMP-9-depleted fractions, there were significant MMP-9 activity 
differences between the lower PUSH score (PUSH ≤11) group and the higher PUSH 
score (PUSH ≥12) group (p<0.05), with the higher PUSH score (PUSH ≥12) group 
displaying a significant increase in Collagen Type I degrading activity as compared 
with both HS and AWF (p<0.01). This could be due to the large levels of MMP-9 
present in these samples, which in turn suggests that the zymograms may well have 
been overloaded. If indeed this did occur, this may explain why statistically 
significant differences between the two clinical groupings were not obtained.  
 
Nevertheless, Tarlton et al. (1999) were able to use gelatin zymography to show a 
statistical correlation between pro-MMP-9 and the increasing severity of the ulcer 
(p=0.006)39. However, the Tarlton et al. (1999) study used wound site specific 
collection techniques, i.e. they collected CWF from the advancing wound margin in a 
deteriorating ulcer and not the ulcer it its entirety; so the results are not directly 
comparable39. In this study, we specifically chose to use a standardised collection 
technique that recovered the wound fluid in its entirety without any added protein 
selection processes, i.e. differential protein absorption and retrieval from wound 
dressings. Furthermore, while the samples were not collected from clinically infected 
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wounds, it is important to recognise that there would still be a bacterial presence in 
the wound, which may then contribute to the wound fluid’s proteolytic activity. The 
extent to which bacterial proteases contribute to the overall amount of MMP activity 
in CWF will be a focus of future studies. Another interesting point to note is that 
while some MMPs have been known to degrade IgG proteins, namely MMP-3 and 
MMP-740, this was not observed to contribute to cleavage of the antibody from the 
resin in these experiments. This could be due to lower levels of these specific MMPs, 
i.e. MMP-3 and -7, in the CWF samples, or indeed, competitive binding of MMP-9 to 
the antibody, which could then potentially block any further interactions. 
 
To further investigate any potential differences in CWF collected from wounds with 
different clinical status, a direct ELISA was used with a different MMP-9 antibody to 
show quantitative levels of MMP-9 in these samples. This technique showed clear 
differences between the levels of MMP-9 present in the two separate groupings. The 
lower PUSH score (PUSH ≤11) group displayed significantly higher levels of MMP-9 
than AWF (p<0.01), as well as significantly lower levels of MMP-9 than the higher 
PUSH score (PUSH ≥12) group (p<0.01). As a result, it appears that there is a strong 
correlation between increased MMP-9 levels in CWF from wounds in the higher 
PUSH score (PUSH ≥12) group compared to AWF samples (p<0.01). This therefore 
suggests that MMP-9 is the predominant protease involved in degrading the 
extracellular matrix in the chronic wound environment and healing could potentially 
be promoted by its attenuation. In contrast, Fray et al. (2003) propose that MMP-2 
and -9 are both essential for wound healing, a process that would therefore be 
impaired if these two proteases were inhibited in chronic ulcer treatments9. However, 
their hypothesis is based on the fact that gelatinases are required for tissue 
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remodelling and for the onset on re-epithelialisation – stages of wound healing that 
normally occur when inflammation has subsided1. Therefore, if significantly increased 
levels of MMP-2 and -9 are present before inflammation has abated, an excessively 
proteolytic environment will continually degrade key growth promoting agents and 
thus will not allow normal wound healing to occur. 
 
In summary, the study reported here demonstrates that the levels of MMP-9 present in 
the CWF samples is statistically significantly higher compared with both HS and 
AWF. When these CWF samples were separated by their clinical score, the fluids 
from the clinically worse ulcers, i.e. those with the higher PUSH scores (PUSH ≥12), 
displayed significantly higher levels of MMP-9 than those from the lower PUSH 
score (PUSH ≤11) group (p<0.01). In addition, it appears that high levels of MMP-9 
activity in CWF are a better indicator of a wound's chronicity than the total protease 
activity levels alone. Further, these data suggest it is not surprising that current topical 
treatments of chronic ulcers with bioactives, e.g. growth factors, have proven to be 
only slightly effective in treating chronic wounds since high levels of proteases can 
rapidly degrade these growth promoting agents41.  
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Tables 
 
Table 1.  Patient clinical data from chronic wound fluid samples. 
 
Patient Age  Sex Sample Code 
Ulcer 
Duration 
(Weeks) 
Ulcer 
Size 
(cm²) 
% 
Reduction 
in wound 
area (from 
baseline) 
Compression 
(mmHg) 
PUSH 
Score 
1 54 F 33 102 44 0 <10 15 
2 79 F 34 102 15 -25 30 - 35 12 
3 76 F 57 162 84 64 30 - 35 15 
4 79 F 89 261 16 0 30 - 40 14 
5 88 M 95 320 10.7 83.7 30 - 35 13 
6 67 F 96 37 16 0 30 - 40 10 
7 77 M 131 550 8 0 20 - 25 10 
8 86 F 142 100 7.1 0 30 - 35 9 
9 75 M 173 20 7 0 30 - 40 10 
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Figure Legends 
 
Figure 1. Collagen Type I zymography demonstrating protease activity 
present in wound fluid samples. Lane 1 is the positive control of MMP-8 (100 ng). 
Lane 2 is HS and lanes 3-5 are AWF samples 1-3 with 5 µg of total protein loaded per 
sample. Lanes 6-14 are CWF samples 1-9 with 500 ng of total protein loaded per 
sample.  
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Figure 2.  Collagen Type IV zymography demonstrating protease activity 
present in wound fluid samples. Lane 1 is the positive control of MMP-9 (10 ng). 
Lane 2 is human serum and lanes 3-5 are AWF samples 1-3 with 10 µg of total 
protein loaded per sample. Lanes 6-14 are CWF samples 1-9 with 1 µg of total protein 
loaded per sample. 
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Figure 3.  GM6001 inhibition of protease activity in CWF-1 confirms the 
MMP specific degradation of Collagen Type I as revealed through zymography. 
(a)  Lane 1 is the positive control of MMP-8 (100 ng). Lane 2 is the untreated 
sample of CWF-1 with 500 ng of total protein loaded. Lanes 3-9 are CWF-1 samples 
(500 ng) treated with increasing concentrations of the specific MMP-inhibitor, 
GM6001, at 1, 3, 10, 30, 100, 300, and 1000 µM at 37 ºC for 24 hours.  
(b) Relative levels of protease activity in CWF-1 samples treated with increasing 
concentrations of GM6001. The MMP-specific inhibition of collagen degrading 
activity was represented quantitatively through densitometric analysis. Levels are 
shown as the % collagen degrading activity, of both the total and also individual 
molecular weight bands, as compared to the untreated sample, ± SEM (n=3). 
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Figure 4. Initial immunoprecipitation of MMP-8 and -13 from CWF samples 
and analysis of enriched fractions through Collagen Type I zymography.  
(a)  Lane 1 contains the positive control of MMP-8 (100 ng). Lanes 2 and 3 are the 
negative controls of Protein A/G and Protein A/G + MMP-8 pAb. Lanes 4 -9 are the 
bound fractions of CWF samples 1-6 with 500 ng of total protein loaded per sample. 
(b)  Lane 1 contains the positive control of a 27 kDa truncated version of MMP-13 
(100 ng). Lanes 2 and 3 are the negative controls of Protein A/G and Protein A/G + 
MMP-13 pAb. Lanes 4 -9 are the bound fractions of CWF samples 1-6 with 500 ng of 
total protein loaded per sample  
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Figure 5. Immunoprecipitation of MMP-9 from wound fluid samples and 
analysis of MMP-9 enriched fractions through Collagen Type I zymography.  
 (a) Lane 1 contains the positive control of MMP-9 (500 pg). Lanes 2 and 3 are the 
negative controls of Protein A/G and Protein A/G + MMP-9 mAb. Lanes 4 -16 are the 
bound fractions of HS, AWF samples 1-3 and CWF samples 1-9 with 500 ng of total 
protein loaded per sample  
(b) Relative levels of MMP-9-bound fractions in individual samples represented 
quantitatively through densitometric analysis. Levels are shown as the mean activity ± 
SEM (n=3). Statistical significance is relative to HS and shown as either * (p<0.05) or 
# (p<0.01) as determined by Tukey’s test. 
(c) Data from (b) is separated into HS, AWF and CWF pooled samples. Statistical 
significance is relative to both HS and AWF and shown as # (p<0.01) as determined 
by Tukey’s test. 
(d) Data from (b) is separated into samples with a higher PUSH score (CWF samples 
1-5, PUSH ≥12) and lower PUSH scores (CWF samples 6-9, PUSH ≤11). A higher 
PUSH score indicates a clinically worse ulcer. Statistical significance is relative to 
both HS and AWF and shown as # (p<0.01) as determined by Tukey’s test. 
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 Figure 6. Immunoprecipitation of MMP-9 from wound fluid samples and 
analysis of MMP-9 depleted fractions through Collagen Type I zymography.  
 (a) Lane 1 contains the positive control of MMP-9 (500 pg). Lanes 2 -14 are the 
unbound fractions of HS, AWF samples 1-3 and CWF samples 1-9 with 500 ng of 
total protein loaded per sample  
(b) Relative levels of MMP-9-unbound fractions in individual samples represented 
quantitatively through densitometric analysis. Levels are shown as the mean activity ± 
SEM (n=3). Statistical significance is relative to HS and shown as either * (p<0.05) or 
# (p<0.01) as determined by Tukey’s test. 
(c) Data from (b) is separated into HS, AWF and CWF pooled samples. Statistical 
significance is relative to both HS and AWF and shown as # (p<0.01) as determined 
by Tukey’s test. 
(d) Data from (b) is separated into samples with a higher PUSH score (CWF samples 
1-5, PUSH ≥12) and lower PUSH scores (CWF samples 6-9, PUSH ≤11). A higher 
PUSH score indicates a clinically worse ulcer. Statistical significance is relative to 
both HS and AWF and shown as # (p<0.01) as determined by Tukey’s test. 
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Figure 7. MMP-9 levels in wound fluid samples analysed through an ELISA. 
Levels are shown as MMP-9 (ng)/total protein (µg) ± SEM (measured in triplicate and 
repeated). 
(a) Data is represented as individual samples. Statistical significance is relative to HS 
and shown as either * (p<0.05) or # (p<0.01) as determined by Tukey’s test. 
(b) Data from (a) is separated into HS, AWF and CWF pooled samples. Statistical 
significance is relative to both HS and AWF and shown as # (p<0.01) as determined 
by Tukey’s test. 
(c) Data from (a) is separated into samples with a higher PUSH score (CWF samples 
1-5, PUSH ≥12) and lower PUSH scores (CWF samples 6-9, PUSH ≤11). A higher 
PUSH score indicates a clinically worse ulcer. Statistical significance is relative to 
both HS and AWF and shown as # (p<0.01) as determined by Tukey’s test. 
 
 
 
